

Wai C. Wong, et al.  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 3

A Marked-Up Version of Amended Claims showing the changes made is attached hereto as **EXHIBIT A**.

**REMARKS**

Claims 1 to 26 were pending in the subject application. By this Amendment, applicants have canceled claims 2, 5, 6, 9, 15, 16, 17, 18, 19, 20, 23 and 26 without prejudice or disclaimer, and amended claims 3, 4, 10, 11, 12, 14, 21 and 24. Accordingly, upon entry of this Amendment, claims 1, 3, 4, 7, 8, 10, 11, 12, 13, 14, 21, 22, 24 and 25 will be pending and under examination.

Applicants have amended claims 3, 4, 10, 11, 12, 14, 21 and 24 to change the claim dependency. Applicants maintain that the amendments to claims 3, 4, 10, 11, 12, 14, 21 and 24 raise no issue of new matter. Accordingly, applicants respectfully request that the Amendment be entered.

**Information Disclosure Statement**

In accordance with the duty of disclosure under 37 C.F.R. §1.56, applicants would like to direct the Examiner's attention to the following references which are listed on the attached Form PTO-1449 (**EXHIBIT 1**). The following references were previously cited in connection with the prosecution of U.S. Serial Number 09/398,861 from which the subject application claims benefit under 35 U.S.C. §120. According to 37 C.F.R. §1.98(d), copies of patents or publications that were previously cited by, or submitted to, the Office in connection with such prior applications need not accompany the Information Disclosure Statement. Accordingly, copies of the following references are not attached to this Information Disclosure Statement:

Wai C. Wong, et al.  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 2

Please cancel claims 2, 5-6, 9, 15-20, 23 and 26 without prejudice to applicants' right to pursue the subject matter of these claims in a future continuation or divisional application.

Please amend the claims 3, 4, 10, 11, 12, 14, 21 and 24 as follows:

--3. (Amended) The compound of claim 1, wherein the compound comprises the (+) enantiomer.--

--4. (Amended) The compound of claim 1, wherein the compound comprises the (-) enantiomer.--

--10. (Amended) The compound of claim 7, wherein p is at least 1 and at least one R<sub>3</sub> is methyl.--

--11. (Amended) The compound of claim 7, wherein at least one R<sub>2</sub> is methyl.--

--12. (Amended) The compound of claim 7, wherein at least one R<sub>2</sub> is bromo.--

--14. (Amended) The compound of claim 7, wherein at least one R<sub>2</sub> is methyl or phenyl.--

--21. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier.--

--24. (Amended) The method of claim 22, wherein the disorder is migraine headache, hypertension or glaucoma.--

Wai C. Wong, et al.  
Serial No.: Not Yet Known  
Filed: Herewith  
Page 4

1. U.S. Patent No. 3,288,805, issued November 29, 1966, Berg, A.;
2. U.S. Patent No. 3,636,219, issued January 18, 1972, Culik, R. and Schneider, J. A.;
3. U.S. Patent No. 4,374,143, issued February 15, 1983, Dolman, H. et al.;
4. U.S. Patent No. 5,028,606, issued July 2, 1991, Venet, M. G., et al.;
5. U.S. Patent No. 5,663,189, issued September 2, 1997, Maurer, P. J., et al.;
6. PCT International Publication No. WO 92/14453, published September 3, 1992;
7. UK Patent Application GB 2206880, published January 18, 1989, Karjalainen, A. J., et al.;
8. Amemiya, Y., et al., "Synthesis and  $\alpha$ -Adrenergic Activities of 2- and 4-Substituted Imidazoline and Imidazole Analogues," J. Med. Chem. (1992) 35: 750-755;
9. Hong, S., et al., "A Structure-Activity Relationship Study of Benzylic Modifications of 4-[1-(1-Naphthyl)ethyl]-1H-imidazoles on  $\alpha_1$ - and  $\alpha_2$ -Adrenergic Receptors," J. Med. Chem. (1994) 37: 2328-2333;
10. von Kretzschmar, R., et al., "Zur Pharmakologie von N-(2-Imidazolin-2-yl)-N-(4-indanyl)amin (Indanazolin), einer neuen vasokonstriktorisch wirksamen Imidavalinverbindung," Arzneim.-Forsch./Drug Res. (1980) 30: 1746-60;

442440  
 442441  
 442442  
 442443  
 442444  
 442445  
 442446  
 442447  
 442448  
 442449  
 442450  
 442451  
 442452  
 442453  
 442454  
 442455  
 442456  
 442457  
 442458  
 442459  
 442460  
 442461  
 442462  
 442463  
 442464  
 442465  
 442466  
 442467  
 442468  
 442469  
 442470  
 442471  
 442472  
 442473  
 442474  
 442475  
 442476  
 442477  
 442478  
 442479  
 442480  
 442481  
 442482  
 442483  
 442484  
 442485  
 442486  
 442487  
 442488  
 442489  
 442490  
 442491  
 442492  
 442493  
 442494  
 442495  
 442496  
 442497  
 442498  
 442499  
 442500  
 442501  
 442502  
 442503  
 442504  
 442505  
 442506  
 442507  
 442508  
 442509  
 442510  
 442511  
 442512  
 442513  
 442514  
 442515  
 442516  
 442517  
 442518  
 442519  
 442520  
 442521  
 442522  
 442523  
 442524  
 442525  
 442526  
 442527  
 442528  
 442529  
 442530  
 442531  
 442532  
 442533  
 442534  
 442535  
 442536  
 442537  
 442538  
 442539  
 442540  
 442541  
 442542  
 442543  
 442544  
 442545  
 442546  
 442547  
 442548  
 442549  
 442550  
 442551  
 442552  
 442553  
 442554  
 442555  
 442556  
 442557  
 442558  
 442559  
 442560  
 442561  
 442562  
 442563  
 442564  
 442565  
 442566  
 442567  
 442568  
 442569  
 442570  
 442571  
 442572  
 442573  
 442574  
 442575  
 442576  
 442577  
 442578  
 442579  
 442580  
 442581  
 442582  
 442583  
 442584  
 442585  
 442586  
 442587  
 442588  
 442589  
 442590  
 442591  
 442592  
 442593  
 442594  
 442595  
 442596  
 442597  
 442598  
 442599  
 442600  
 442601  
 442602  
 442603  
 442604  
 442605  
 442606  
 442607  
 442608  
 442609  
 442610  
 442611  
 442612  
 442613  
 442614  
 442615  
 442616  
 442617  
 442618  
 442619  
 442620  
 442621  
 442622  
 442623  
 442624  
 442625  
 442626  
 442627  
 442628  
 442629  
 442630  
 442631  
 442632  
 442633  
 442634  
 442635  
 442636  
 442637  
 442638  
 442639  
 442640  
 442641  
 442642  
 442643  
 442644  
 442645  
 442646  
 442647  
 442648  
 442649  
 442650  
 442651  
 442652  
 442653  
 442654  
 442655  
 442656  
 442657  
 442658  
 442659  
 442660  
 442661  
 442662  
 442663  
 442664  
 442665  
 442666  
 442667  
 442668  
 442669  
 442670  
 442671  
 442672  
 442673  
 442674  
 442675  
 442676  
 442677  
 442678  
 442679  
 442680  
 442681  
 442682  
 442683  
 442684  
 442685  
 442686  
 442687  
 442688  
 442689  
 442690  
 442691  
 442692  
 442693  
 442694  
 442695  
 442696  
 442697  
 442698  
 442699  
 442700  
 442701  
 442702  
 442703  
 442704  
 442705  
 442706  
 442707  
 442708  
 442709  
 442710  
 442711  
 442712  
 442713  
 442714  
 442715  
 442716  
 442717  
 442718  
 442719  
 442720  
 442721  
 442722  
 442723  
 442724  
 442725  
 442726  
 442727  
 442728  
 442729  
 442730  
 442731  
 442732  
 442733  
 442734  
 442735  
 442736  
 442737  
 442738  
 442739  
 442740  
 442741  
 442742  
 442743  
 442744  
 442745  
 442746  
 442747  
 442748  
 442749  
 442750  
 442751  
 442752  
 442753  
 442754  
 442755  
 442756  
 442757  
 442758  
 442759  
 442760  
 442761  
 442762  
 442763  
 442764  
 442765  
 442766  
 442767  
 442768  
 442769  
 442770  
 442771  
 442772  
 442773  
 442774  
 442775  
 442776  
 442777  
 442778  
 442779  
 442780  
 442781  
 442782  
 442783  
 442784  
 442785  
 442786  
 442787  
 442788  
 442789  
 442790  
 442791  
 442792  
 442793  
 442794  
 442795  
 442796  
 442797  
 442798  
 442799  
 442800  
 442801  
 442802  
 442803  
 442804  
 442805  
 442806  
 442807  
 442808  
 442809  
 442810  
 442811

- If a telephone conference would be of assistance in advancing the prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

Respectfully submitted,

John P. White  
Registration No. 28,678  
Attorney for Applicants  
Cooper & Dunham LLP  
1185 Ave of the Americas  
New York, New York 10036  
(212) 278-0400

Marked-up Version Of Amended Claims

Additions to the text are indicated by underlining; deletions are indicated by square brackets.

- 3. (Amended) The compound of claim 1 [or 2], wherein the compound comprises the (+) enantiomer.--
- 4. (Amended) The compound of claim 1 [or 2], wherein the compound comprises the (-) enantiomer.--
- 10. (Amended) The compound of claim [5] 7, wherein p is at least 1 and at least one R<sub>3</sub> is methyl.--
- 11. (Amended) The compound of claim [5] 7, wherein at least one R<sub>2</sub> is methyl.--
- 12. (Amended) The compound of claim [6] 7, wherein at least one R<sub>2</sub> is bromo.--
- 14. (Amended) The compound of claim [9] 7, wherein at least one R<sub>2</sub> is methyl or phenyl.--
- 21. (Amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 [or 2] and a pharmaceutically acceptable carrier.--
- 24. (Amended) The method of claim 22 [or 23], wherein the disorder is migraine headache, hypertension or glaucoma.--

**EXHIBIT A**  
Wai C. Wong, et al.  
Serial No.: Not Yet Known  
Filed: Herewith